Global microRNA profiles and signaling pathways in the development of cardiac hypertrophy

Brazilian Journal of Medical and Biological Research

Volumn 47, Issue 5, 2014, Pages 361-368

  Feng, H J ^a   Ouyang, W ^a   Liu, J H ^a   Sun, Y G ^a   Hu, R ^a   Huang, L H ^a   Xian, J L ^a   Jing, C F ^b   Zhou, M J ^b  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

Biomarker; Cardiac hypertrophy; Signaling pathway

Indexed keywords

BIOLOGICAL MARKER; MICRORNA;

AGAR GEL ELECTROPHORESIS; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BIOINFORMATICS; CONTROLLED STUDY; DOWN REGULATION; HEART VENTRICLE HYPERTROPHY; HISTOPATHOLOGY; MALE; MICROARRAY ANALYSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PROGNOSIS; RAT; RNA ISOLATION; SIGNAL TRANSDUCTION; UPREGULATION; WNT SIGNALING PATHWAY; ALGORITHM; ANIMAL; AORTA; BIOLOGY; CARDIOMEGALY; DISEASE MODEL; GENETICS; HEART MUSCLE CELL; METABOLISM; PATHOLOGY; SPRAGUE DAWLEY RAT; STENOSIS, OCCLUSION AND OBSTRUCTION; SURGERY;

ALGORITHMS; ANIMALS; AORTA; BIOLOGICAL MARKERS; CARDIOMEGALY; COMPUTATIONAL BIOLOGY; CONSTRICTION, PATHOLOGIC; DISEASE MODELS, ANIMAL; DOWN-REGULATION; MALE; MICRORNAS; MYOCYTES, CARDIAC; PROGNOSIS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 84900004426     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/1414-431X20142937     Document Type: Article

References (29)

1. Dettmeyer R, Schmidt P, Kandolf R, Madea B. Evolution of dilated cardiomyopathy (DCM) from idiopathic hypertrophic cardiomyopathy (IHCM) vs inflammatory dilated cardiomyopathy (DCMi): a rare case of sudden death in an 8-year-old boy. Pathol Res Pract 2004; 200: 411-415, doi: 10.1016/j.prp.2004.03.005.
2. Rohini A, Agrawal N, Koyani CN, Singh R. Molecular targets and regulators of cardiac hypertrophy. Pharmacol Res 2010; 61: 269-280, doi: 10.1016/j.phrs.2009.11.012.
3. Dorn GW, Robbins J, Sugden PH. Phenotyping hypertrophy: eschew obfuscation. Circ Res 2003; 92: 1171-1175, doi: 10.1161/01.RES.0000077012.11088.BC.
4. Aaronson KD, Sackner-Bernstein J. Risk of death associated with nesiritide in patients with acutely decompensated heart failure. JAMA 2006; 296: 1465-1466, doi: 10.1001/jama.296.12.1465.
5. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-297, doi: 10.1016/S0092-8674(04)00045-5.
6. Cuellar TL, McManus MT. MicroRNAs and endocrine biology. J Endocrinol 2005; 187: 327-332, doi: 10.1677/joe.1.06426.
7. Oliveira-Carvalho V, Carvalho VO, Silva MM, Guimaraes GV, Bocchi EA. MicroRNAs: a new paradigm in the treatment and diagnosis of heart failure? Arq Bras Cardiol 2012; 98: 362-369, doi: 10.1590/S0066-782X2012000400011.
8. van Rooij E, Sutherland LB, Liu N, Williams AH, McAnally J, Gerard RD, et al. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci U S A 2006; 103: 18255-18260, doi: 10.1073/pnas.0608791103.
9. Gladka MM, da Costa Martins PA, De Windt LJ. Small changes can make a big difference - microRNA regulation of cardiac hypertrophy. J Mol Cell Cardiol 2012; 52: 74-82, doi: 10.1016/j.yjmcc.2011.09.015.
10. Callis TE, Wang DZ. Taking microRNAs to heart. Trends Mol Med 2008; 14: 254-260, doi: 10.1016/j.molmed.2008.03.006.
11. Elia L, Contu R, Quintavalle M, Varrone F, Chimenti C, Russo MA, et al. Reciprocal regulation of microRNA-1 and insulin-like growth factor-1 signal transduction cascade in cardiac and skeletal muscle in physiological and pathological conditions. Circulation 2009; 120: 2377-2385, doi: 10.1161/CIRCULATIONAHA.109.879429.
12. Sayed D, Hong C, Chen IY, Lypowy J, Abdellatif M. MicroRNAs play an essential role in the development of cardiac hypertrophy. Circ Res 2007; 100: 416-424, doi: 10.1161/01.RES.0000257913.42552.23.
13. Ikeda S, He A, Kong SW, Lu J, Bejar R, Bodyak N, et al. MicroRNA-1 negatively regulates expression of the hypertrophy-associated calmodulin and Mef2a genes. Mol Cell Biol 2009; 29: 2193-2204, doi: 10.1128/MCB.01222-08.
14. Li P. MicroRNAs in cardiac apoptosis. J Cardiovasc Transl Res 2010; 3: 219-224, doi: 10.1007/s12265-010-9175-9.
15. Su H, Yang JR, Xu T, Huang J, Xu L, Yuan Y, et al. MicroRNA-101, downregulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity. Cancer Res 2009; 69: 1135-1142, doi: 10.1158/0008-5472.CAN-08-2886.
16. Hosoda T, Zheng H, Cabral-da-Silva M, Sanada F, Ide-Iwata N, Ogorek B, et al. Human cardiac stem cell differentiation is regulated by a mircrine mechanism. Circulation 2011; 123: 1287-1296, doi: 10.1161/CIRCULATIONAHA.110.982918.
17. Matkovich SJ, Hu Y, Eschenbacher WH, Dorn LE, Dorn GW. Direct and indirect involvement of microRNA-499 in clinical and experimental cardiomyopathy. Circ Res 2012; 111: 521-531, doi: 10.1161/CIRCRESAHA.112.265736.
18. Ikeda S, Kong SW, Lu J, Bisping E, Zhang H, Allen PD, et al. AlteredmicroRNA expression in human heart disease. Physiol Genomics 2007; 31: 367-373, doi: 10.1152/physiolgenomics.00144.2007.
19. Kartha RV, Subramanian S. MicroRNAs in cardiovascular diseases: biology and potential clinical applications. J Cardiovasc Transl Res 2010; 3: 256-270, doi: 10.1007/s12265-010-9172-z.
20. Thum T, Galuppo P, Wolf C, Fiedler J, Kneitz S, van Laake LW, et al. MicroRNAs in the human heart: a clue to fetal gene reprogramming in heart failure. Circulation 2007; 116: 258-267, doi: 10.1161/CIRCULATIONAHA.107.687947.
21. Fang Y, Shi C, Manduchi E, Civelek M, Davies PF. MicroRNA-10a regulation of proinflammatory phenotype in athero-susceptible endothelium in vivo and in vitro. Proc Natl Acad Sci U S A 2010; 107: 13450-13455, doi: 10.1073/pnas.1002120107.
22. Smits M, Mir SE, Nilsson RJ, van der Stoop PM, Niers JM, Marquez VE, et al. Down-regulation of miR-101 in endothelial cells promotes blood vessel formation through reduced repression of EZH2. PLoS One 2011; 6: e16282, doi: 10.1371/journal.pone.0016282.
23. Zhang X, Wang X, Zhu H, Zhu C, Wang Y, Pu WT, et al. Synergistic effects of the GATA-4-mediated miR-144/451 cluster in protection against simulated ischemia/reperfusioninduced cardiomyocyte death. J Mol Cell Cardiol 2010; 49: 841-850, doi: 10.1016/j.yjmcc.2010.08.007.
24. Creemers EE, Pinto YM. Molecular mechanisms that control interstitial fibrosis in the pressure-overloaded heart. Cardiovasc Res 2011; 89: 265-272, doi: 10.1093/cvr/cvq308.
25. Fontana L, Sorrentino A, Condorelli G, Peschle C. Role of microRNAs in haemopoiesis, heart hypertrophy and cancer. Biochem Soc Trans 2008; 36: 1206-1210, doi: 10.1042/BST0361206.
26. Thum T, Catalucci D, Bauersachs J. MicroRNAs: novel regulators in cardiac development and disease. Cardiovasc Res 2008; 79: 562-570, doi: 10.1093/cvr/cvn137.
27. Krutzfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M, et al. Silencing of microRNAs in vivo with 'antagomirs'. Nature 2005; 438: 685-689, doi: 10.1038/nature04303.
28. van Rooij E, Sutherland LB, Qi X, Richardson JA, Hill J, Olson EN. Control of stress-dependent cardiac growth and gene expression by a microRNA. Science 2007; 316: 575-579, doi: 10.1126/science.1139089.
29. Montgomery RL, Hullinger TG, Semus HM, Dickinson BA, Seto AG, Lynch JM, et al. Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure. Circulation 2011; 124: 1537-1547, doi: 10.1161/CIRCULATIONAHA.111.030932.